Liquid Biopsy: General Concepts

Poulet, Geoffroy; Massias, Joséphine; Taly, Valérie

doi:10.1159/000499337

Cited by 247 publications

(172 citation statements)

References 59 publications

Supporting

Mentioning

154

Contrasting

Unclassified

Order By: Relevance

“…Most biomarker research in cancer focus on quantifying genetic alterations within the tumor and tumor cells. Liquid biopsies are increasingly tested as novel cancer biomarkers by evaluating the so-called 'tumor circulome' consisting of circulating tumor nucleic acids (ctDNA and ctRNA), circulating tumor cells (CTCs), and tumor extracellular vesicles [1,2]. However, the potential of evaluating circulating proteins derived from the tumor microenvironment as novel liquid biopsies is undervalued.…”

Section: Introductionmentioning

confidence: 99%

Post-translational modifications of vimentin reflect different pathological processes associated with non-small cell lung cancer and chronic obstructive pulmonary disease

2019

View full text Add to dashboard Cite

Introduction: Vimentin has shown to be highly implicated in cancer initiation and progression. Vimentin is often a target of post-translational modifications (PTMs) which can be disease specific, thus targeting these specific modifications can be of high biomarker potential. In this study we set out to evaluate the biological relevance and serum biomarker potential of citrullinated vimentin (VICM) and non-citrullinated vimentin (VIM) in non-small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD). Methods: A competitive ELISA targeting VIM was developed and quantified in serum from patients with NSCLC and COPD. VIM was compared with levels of VICM in the same indications. Results: VIM was significantly increased in NSCLC (n = 100) compared to healthy controls (n = 67) in two independent cohorts (p = 0.0003 and p < 0.0001). Furthermore, VIM was highly increased in late stages of NSCLC (p = 0.001), however VIM was not increased in COPD patients (n = 10). Contrarily, serum levels of VICM was not increased in late stages of NSCLC, but highly elevated in patients with COPD (p < 0.0001). Conclusions: These findings suggest a biomarker potential of VIM in NSCLC. Our findings also indicate that PTMs of vimentin are highly relevant and that targeting these modifications can have differential biomarker potential.

show abstract

Section: Introductionmentioning

confidence: 99%

Post-translational modifications of vimentin reflect different pathological processes associated with non-small cell lung cancer and chronic obstructive pulmonary disease

2019

View full text Add to dashboard Cite

show abstract

“…Blood circulating biomarkers are currently used in research and have been suggested for tumor characterization to set a personalized target therapy [e.g., epidermal growth factor receptor (EGFR) mutation profile in lung carcinoma] in clinical practice. Despite the great development of droplet-based digital PCR (ddPCR) and the various optimizations of Next Generation Sequencing technologies (NGS), for both CTCs and ctDNA assays, there is no standardization starting from the pre-analytical phase through the analytical procedures to platform/technological methods [3][4][5] .…”

Section: Lb: Liquid Biopsy; Ec: Endometrial Cancermentioning

confidence: 99%

Liquid biopsy in endometrial cancer

Malentacchi¹,

Sgromo²,

Antonuzzo³

et al. 2020

JCMT

View full text Add to dashboard Cite

Liquid biopsy (LB) is an emerging tool for the evaluation of relapse in several cancers and nowadays is used in lung cancer for primary detection and molecular characterization when tumoral tissue is not available. It can represent an innovative biospecimen for the screening, diagnosis, and monitoring of all types of cancer and for monitoring of therapeutic efficacy. LB includes several biofluids such as blood, urine, peritoneal fluid/lavage, and analytes (circulating tumor cells, circulating tumor DNA, long noncoding RNA, microRNA, vesicles, mRNA, and protein) that can play different roles in diagnosis, prognosis, and patient management as well as in the improvement of the knowledge of cancer evolution. Endometrial cancer (EC) is a tumor usually detected at low stage with a good prognosis, but few low risk cases, unexpectedly, can evolve to bad prognosis. Up to now, no molecular target exists to treat advanced stage or to define the evolution of low stage EC. This review focuses on how the LB may help in the management and characterization of patients affected by EC.

show abstract

“…Firstly, and mainly, tissue samples might not fully represent tumor heterogeneity, constituting a limitation for accurate outcome prediction and treatment efficacy [5,6]. Moreover, early-stage tumor, residual disease, and early recurrence detection might be difficult, since tissue biopsy sampling requires a highly invasive intervention with risk of complications, and, depending on the tumor anatomical location, may be extremely difficult to obtain [4,7]. Therefore, a minimally invasive method that allows for cancer detection at an early stage and patients' follow-up is essential.…”

Section: Introductionmentioning

confidence: 99%

DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types

Constâncio

Nunes

Henrique

et al. 2020

Cells

141

117

View full text Add to dashboard Cite

Lung, breast, colorectal, and prostate cancers are the most incident worldwide. Optimal population-based cancer screening methods remain an unmet need, since cancer detection at early stages increases the prospects of successful and curative treatment, leading to a lower incidence of recurrences. Moreover, the current parameters for cancer patients’ stratification have been associated with divergent outcomes. Therefore, new biomarkers that could aid in cancer detection and prognosis, preferably detected by minimally invasive methods are of major importance. Aberrant DNA methylation is an early event in cancer development and may be detected in circulating cell-free DNA (ccfDNA), constituting a valuable cancer biomarker. Furthermore, DNA methylation is a stable alteration that can be easily and rapidly quantified by methylation-specific PCR methods. Thus, the main goal of this review is to provide an overview of the most important studies that report methylation biomarkers for the detection and prognosis of the four major cancers after a critical analysis of the available literature. DNA methylation-based biomarkers show promise for cancer detection and management, with some studies describing a “PanCancer” detection approach for the simultaneous detection of several cancer types. Nonetheless, DNA methylation biomarkers still lack large-scale validation, precluding implementation in clinical practice.

show abstract

Liquid Biopsy: General Concepts

Cited by 247 publications

References 59 publications

Post-translational modifications of vimentin reflect different pathological processes associated with non-small cell lung cancer and chronic obstructive pulmonary disease

Post-translational modifications of vimentin reflect different pathological processes associated with non-small cell lung cancer and chronic obstructive pulmonary disease

Liquid biopsy in endometrial cancer

DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types

Contact Info

Product

Resources

About